29450-1-AP
antibody from Proteintech Group
Targeting: BRCA2
BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11
Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 29450-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- BRCA2 antibody
- Antibody type
- Polyclonal
- Description
- BRCA2 antibody (Cat. #29450-1-AP) is a rabbit polyclonal antibody that shows reactivity with Human and has been validated for the following applications: WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells.
A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma.
The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin.
Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
Batenburg NL, Sowa DJ, Walker JR, Andres SN, Zhu XD
Nucleic acids research 2024 May 22;52(9):5067-5087
Nucleic acids research 2024 May 22;52(9):5067-5087
A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma.
Fu Q, Yi B, Su Q, Huang Y, Wang L, Zhang Z
Aging 2023 Nov 22;15(22):13213-13238
Aging 2023 Nov 22;15(22):13213-13238
The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
Li Y, Chen Z, Peng J, Yuan C, Yan S, Yang N, Li P, Kong B
Oncogene 2023 Jul;42(31):2386-2401
Oncogene 2023 Jul;42(31):2386-2401
CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin.
Batenburg NL, Walker JR, Zhu XD
International journal of molecular sciences 2023 Aug 4;24(15)
International journal of molecular sciences 2023 Aug 4;24(15)
Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
Chang T, Lian Z, Ma S, Liang Z, Ma X, Wen X, Wang Y, Liu R
The Prostate 2023 Apr;83(5):470-486
The Prostate 2023 Apr;83(5):470-486
No comments: Submit comment
No validations: Submit validation data